Eledon Pharmaceuticals, Inc. Comprehensive Income
Eledon Pharmaceuticals, Inc. (ELDN) reported Comprehensive Income of -$31.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$31.67M.
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$39.12M.
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$10.43M.
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$17.40M, a 122.58% decline year-over-year.
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$45.62M.
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$36.18M.
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$37.91M.
- Eledon Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2015 was -$45.14M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.67M 10-Q · filed 2026-08-13 | -$70.79M 10-Q · filed 2026-08-13 | -$81.22M derived: sum of 3 quarters · filed 2026-08-13 | -$98.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$39.12M 10-Q · filed 2026-05-13 | -$49.55M derived: sum of 2 quarters · filed 2026-05-13 | -$66.95M derived: sum of 3 quarters · filed 2026-05-13 | -$78.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$10.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$27.83M derived: sum of 2 quarters · filed 2026-03-19 | -$39.08M derived: sum of 3 quarters · filed 2026-08-13 | -$45.62M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$17.40M 10-Q · filed 2025-11-14 | -$28.65M derived: sum of 2 quarters · filed 2026-08-13 | -$35.19M 10-Q · filed 2025-11-14 | -$79.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$11.25M 10-Q · filed 2026-08-13 | -$17.79M 10-Q · filed 2026-08-13 | -$62.50M derived: sum of 3 quarters · filed 2026-08-13 | $14.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$6.54M 10-Q · filed 2026-05-13 | -$51.26M derived: sum of 2 quarters · filed 2026-05-13 | $25.82M derived: sum of 3 quarters · filed 2026-05-13 | -$19.09M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$44.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $32.35M derived: sum of 2 quarters · filed 2026-03-19 | -$12.55M derived: sum of 3 quarters · filed 2026-03-19 | -$36.18M 10-K · filed 2026-03-19 |
| 2024-09-30 | $77.07M 10-Q · filed 2025-11-14 | $32.17M derived: sum of 2 quarters · filed 2025-11-14 | $8.54M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | -$44.91M 10-Q · filed 2025-08-14 | -$68.54M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$23.63M 10-Q/A · filed 2025-08-14 | |||
| 2023-09-30 | -$9.91M 10-Q · filed 2024-11-12 | -$86.44M 10-Q · filed 2024-11-12 | ||
| 2017-03-31 | -$3.87M 10-Q · filed 2017-05-03 | -$7.61M derived: sum of 2 quarters · filed 2017-05-03 | -$16.88M derived: sum of 3 quarters · filed 2017-05-03 | -$30.39M derived: sum of 4 quarters · filed 2017-05-03 |
| 2016-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$13.01M derived: sum of 2 quarters · filed 2017-03-03 | -$26.53M derived: sum of 3 quarters · filed 2017-03-03 | -$37.91M 10-K · filed 2017-03-03 |
| 2016-09-30 | -$9.27M 10-Q · filed 2016-11-03 | -$22.79M derived: sum of 2 quarters · filed 2016-11-03 | -$34.16M 10-Q · filed 2016-11-03 | -$45.24M derived: sum of 4 quarters · filed 2017-05-03 |
| 2016-06-30 | -$13.52M 10-Q · filed 2016-08-04 | -$24.89M 10-Q · filed 2016-08-04 | -$35.97M derived: sum of 3 quarters · filed 2017-05-03 | -$47.81M derived: sum of 4 quarters · filed 2017-05-03 |
| 2016-03-31 | -$11.38M 10-Q · filed 2017-05-03 | -$22.46M derived: sum of 2 quarters · filed 2017-05-03 | -$34.30M derived: sum of 3 quarters · filed 2017-05-03 | -$43.26M derived: sum of 4 quarters · filed 2017-05-03 |
| 2015-12-31 | -$11.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$22.92M derived: sum of 2 quarters · filed 2017-03-03 | -$31.88M derived: sum of 3 quarters · filed 2017-03-03 | -$45.14M 10-K · filed 2017-03-03 |
| 2015-09-30 | -$11.84M 10-Q · filed 2016-11-03 | -$20.80M derived: sum of 2 quarters · filed 2016-11-03 | -$34.06M 10-Q · filed 2016-11-03 | -$40.27M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-06-30 | -$8.96M 10-Q · filed 2016-08-04 | -$22.22M 10-Q · filed 2016-08-04 | -$28.43M derived: sum of 3 quarters · filed 2017-03-03 | -$34.82M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-03-31 | -$13.26M 10-Q · filed 2016-05-10 | -$19.47M derived: sum of 2 quarters · filed 2017-03-03 | -$25.86M derived: sum of 3 quarters · filed 2017-03-03 | -$31.71M derived: sum of 4 quarters · filed 2017-03-03 |
| 2014-12-31 | -$6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$12.60M derived: sum of 2 quarters · filed 2017-03-03 | -$18.45M derived: sum of 3 quarters · filed 2017-03-03 | -$23.30M 10-K · filed 2017-03-03 |
| 2014-09-30 | -$6.39M 10-Q · filed 2015-11-10 | -$12.24M derived: sum of 2 quarters · filed 2015-11-10 | -$17.09M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | -$5.85M 10-Q · filed 2015-08-12 | -$10.70M 10-Q · filed 2015-08-12 | ||
| 2013-12-31 | -$15.72M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |